001630.KS
Chong Kun Dang Holdings Corp.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 38,900.00
−0.51%Year over year
Reported trailing growth
- Revenue
- +1.4%
- EBITDA
- -96.8%
- EBIT
- +31.2%
- EPS
- +149.6%
- Free cash flow
- +146.7%
- Operating cash flow
- +566.0%
Forward estimates
Based on analyst estimates
- Revenue
- -41.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.8%
- EBITDA
- +95.9%
- EBIT
- +32.6%
- Net income
- +235.1%
- EPS
- +238.5%
- Free cash flow
- +99.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026